Novartis Remibrutinib Trial Data Drawn to Neurologist Poll
FirstWord is surveying neurologists on the oral BTK inhibitor's Phase III multiple sclerosis results presented at MSToronto2026.
Updated on Nov. 4, 2026 in Stroke
FirstWord is polling neurologists on Novartis' remibrutinib, an oral BTK inhibitor candidate for relapsing multiple sclerosis, after detailed Phase III REMODEL-1 and REMODEL-2 results were presented at MSToronto2026. The annualised relapse rates did not meet some investors' expectations.
Why it matters
Remibrutinib may be positioned earlier in the multiple sclerosis disease trajectory, and it lacks the liver toxicity seen with other drugs in its class. Several rival BTK inhibitors have faced partial clinical holds over liver-induced drug injury.
The Phase III relapse data come from REMODEL-1 and REMODEL-2, and Novartis projects $4 billion in peak sales, but how physicians will judge the clinical significance of these results is not yet known.
The players
Novartis
Novartis is the Swiss pharmaceutical company developing remibrutinib, an oral BTK inhibitor candidate in relapsing multiple sclerosis.
FirstWord Pharma
FirstWord Pharma is a pharmaceutical intelligence publisher that is polling neurologists on remibrutinib.
The details
FirstWord is asking neurologists how clinically significant the remibrutinib results are and how reductions in disability progression influence their view of the drug. Poll results will be published soon for FirstWord Pharma PLUS subscribers.
Timeline
MSToronto2026 presented the REMODEL-1 and REMODEL-2 results in 2026.
The FirstWord article was published on November 4, 2026.
Big Picture
Remibrutinib's lack of the liver toxicity that led to partial clinical holds for fenebrutinib, tolebrutinib, evobrutinib and orelabrutinib sets it apart within the BTK inhibitor class in multiple sclerosis.
If approved, remibrutinib could offer an oral option for relapsing multiple sclerosis patients with a different liver safety profile than some competing BTK inhibitors. Its ultimate role in treatment will depend on how neurologists weigh the relapse data against existing therapies.
The takeaway
Neurologists are weighing whether remibrutinib's relapse results and safety profile justify a place earlier in the multiple sclerosis treatment course. Poll results will help show how the clinical community is reading the data.
Further reading
Explore more on Stroke and related neurological conditions.
Source note: This article includes information reported by Firstwordpharma.
